

# **Mountain States Genetics Regional Collaborative Center**

## **Laboratory Quality Assurance**

***Exchange of blood spots for educational purposes to improve quality of newborn screening by MS/MS.***

**PI: Marzia Pasquali, PhD, FACMG  
University of Utah**

*18 May 2007*

# Background

- **Newborn screening by tandem mass spectrometry (MS/MS) has now been implemented in most states.**
- **Challenges with MS/MS cut-offs and interpretation of results have been addressed by the Region 4 Laboratory Quality Improvement activity.**
- **There is still some unresolved issues on how to deal with borderline/abnormal values reflecting iatrogenic effects.**

# Goal of the project

- **Improve recognition of abnormal patterns**
- **Decrease the number of unnecessary confirmatory tests**
- **Promote the use of 2<sup>nd</sup> tier tests**
- **Decrease the number of false positives (and false negatives in some cases)**

# Methods

- **The goal will be achieved by:**
  - Encouraging all the states within Region 6 to participate in Region 4 activity and attend the training sessions
  - Sending educational challenges (blood spots from real patients with metabolic disorders or with clinical conditions resulting in abnormal amino acids or acylcarnitines)
  - Compiling a complete report that will address not just the analytical part of testing, but also the follow up/clinical aspect

# Existing programs

- **CDC proficiency testing**
  - Quantitative assessment of several analytes, including amino acids and acylcarnitines
- **ERNDIM**
  - Qualitative assessment of blood spots, often from adults or patients on therapy

# *Newborn screening is a program*



# **Diseases to include in the educational challenges**

- **Metabolic disorders detected by MS/MS**
- **Endocrine disorders (CAH) when either the primary screen or a 2<sup>nd</sup> tier test is performed by MS/MS**
- **Hyperalimentation, antibiotics, special diets, medications**
- **Other disorders can also be included**

# Educational challenges

- **Markers used**
- **2<sup>nd</sup> tier tests used (if applicable)**
- **Significance**
- **Recommendations for follow-up**
  - **Confirmatory tests**
  - **Metabolic referral**
  - **Urgency**
- **Involvement of Technical Supervisor/Medical Director/Metabolic consultant**





# Evaluation Forms

- **Clinical description of the patient**
- **Abnormal metabolites present in the sample**
- **Explanation of these abnormalities**
- **If applicable, the importance of 2<sup>nd</sup> tier tests**
- **Recommendations for follow-up**
- **Lessons learned from different cases**


# Example

## Congenital Adrenal Hyperplasia (receiving corticosteroids)

- Low Birth Weight (g 2,210) with severe respiratory distress initiated on corticosteroids before collection of newborn screening sample.
- MS/MS test results:
  - 17-hydroxyprogesterone: 7.3 ng/mL (Normal)
  - androstenedione: 4 ng/mL (Normal)
  - cortisol: 1.7 ng/mL (LOW)
  - $(17\text{-OHP} + \text{androstenedione})/\text{cortisol} = 6.7$   
(Abnormal)

# Steroid profile by UPLC-MS/MS

Waters Premiere/Acquity



# **Distribution of information**


- **The evaluation forms will be distributed by electronic mail**
- **One meeting/year will be organized to discuss the educational challenges**
- **Results will also be discussed at the regional meetings**
- **Tracking of the performance over time will determine the impact of the training sessions and the educational challenges**

# Challenges

- **Obtaining blood from patients**
  - **Need for participation of many centers in order to increase the number of cases**
  - **Need for participation of NICUs to identify factors affecting NBS results**
  - **Need for consent forms that can be shared by other states**

# Challenges

- **Consent forms**
  - We will develop general consent forms and we will assist with IRB submission
- **Tracking of data**
  - Develop a database containing information about participating laboratories
  - Metrics to objectively evaluate results and compare them over time will be developed



**Region 6**

**Arizona  
MS/MS**

**Colorado  
MS/MS**

**Montana  
(No uniform  
panel)**

**Nevada**

**New  
Mexico**

**Texas  
MS/MS**

**Utah  
MS/MS  
(ARUP)**

**Wyoming**

**Wisconsin  
MS/MS**

**Oregon  
MS/MS**

# Enrollment

- **Although this project will start as a regional effort, enrollment will be open to every laboratory performing NBS by MS/MS**
- **There will be no cost for laboratories to participate**



# Requirements

- **Participating laboratories will be asked to:**
  - **Analyze 2-3 sets of blood spots twice per year**
  - **Fill the results form**
  - **E-mail the results**
  - **Attend one meeting/year**

# Summary

- **This project will:**
  - **Improve the quality of screening**
  - **Increase awareness and education about metabolic disorders**
  - **Complement the activities of Region 4 collaborative project and the existing proficiency testing run by the CDC**